Abstract
Conflicting results from clinical trials have contributed to a lack of consensus about cardioprotective effects of omega-3 (n-3) highly unsaturated fatty acids (HUFA). Although the VITAL trial did not demonstrate an overall benefit of n-3 HUFA supplementation on composite cardiovascular disease (CVD) and cancer outcomes, the substantial enrollment of African Americans (AfAm) afforded a unique opportunity for a post-hoc analysis of racial differences in the supplementation response. We employed propensity score matching to address potential covariate imbalances between AfAm and European American (EuAm) participants in VITAL (N=3,766 participants). Using Kaplan-Meier curves and two machine learning methodologies, we found that n-3 HUFA supplementation was significantly associated with a reduced risk of myocardial infarction (MI) exclusively in the AfAm subgroup, as evidenced by an odds ratio of 0.17 (95% CI [0.048, 0.59]). These findings indicate a potential cardioprotective benefit of n-3 supplementation in AfAm, specifically in reducing MI risks; a risk not identified in EuAm. Further investigation of n-3 HUFA effects through a hypothesis-driven randomized clinical trial among AfAm is needed to test a race-specific response that may inform recommendations for n-3 HUFA supplementation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by National Center for Complementary and Integrative Health [R01 AT008621; FHC] and U.S. Department of Agriculture [ARZT-1361680-H23-157; FHC]
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used (or will use) ONLY openly available human data that were originally located at https://data.projectdatasphere.org/projectdatasphere/html/content/454
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.